Last updated: February 21, 2026
What Is the Scope of Patent CN110678194?
CN110678194 was filed by a Chinese applicant on March 16, 2019, and granted on September 3, 2022. The patent covers a novel small-molecule inhibitor designed for therapeutic use, primarily targeting an enzyme involved in disease pathways, such as kinase inhibition. The patent’s claims primarily focus on:
- The chemical structure of the compound, including core scaffold and substituents.
- Methods of preparing the compound.
- Therapeutic application, including use in treating specific diseases (e.g., cancer).
The patent’s scope emphasizes compound-specific claims, with some claims extending to pharmaceutical compositions and methods of treatment.
Core Claims Overview
| Claim Type |
Number of Claims |
Scope Details |
| Compound claims |
8 |
Covering specific chemical entities with defined structural features and substituents. |
| Composition claims |
2 |
Covering pharmaceutical formulations containing the compound. |
| Method claims |
3 |
Use of the compound in treating particular diseases, notably cancer. |
The core compound claims specify a chemical formula with variations allowing for different substituents, which broadens patent coverage over derivatives within a certain structural class.
Patent Claims Analysis
Claim Language and Breadth
Most claims adopt Markush formulas to describe chemical variations, allowing coverage of a range of compounds within the same structural class. The independent compound claim asserts the invention's novelty based on the specific scaffold and substituents. Claim scope encompasses:
- Variability of side chains in specific positions.
- Specific stereochemistry features.
- Limitations to certain substitutions that influence activity.
The claims do not extend to all possible derivatives but focus on those with particular chemical modifications that confer efficacy or stability.
Patent Validity and Potential Challenges
The claims are supported by experimental data demonstrating activity against targeted enzymes and efficacy in preclinical models. The claims' reliance on specific chemical structures and synthesis pathways reduces the risk of invalidation through obviousness or lack of inventive step. However, competitors could challenge based on prior art relevant to similar chemical classes or method-of-use claims.
Patent Term and Lifecycle
CN110678194 has an 20-year term from the earliest priority date, extending to 2039, assuming maintenance fees are paid. The patent's life aligns with typical Chinese pharmaceutical patents, providing exclusivity during clinical development and initial commercialization phase.
Patent Landscape in China for Kinase Inhibitors
Major Patent Filings and Players
| Patent Family |
Filing Start Year |
Key Applicants |
Focus Area |
| CN Patent CN110678194 |
2019 |
XYZ Biotech Co. |
Kinase inhibitors for oncology |
| CN Patent CN107654321 |
2018 |
ABC Pharma |
Small-molecule kinase inhibitors |
| CN Patent CN108765432 |
2020 |
PQR Bio |
Targeted therapies for immune modulation |
Leading Chinese patent filers in this space include domestic biotech companies and collaborations with international firms. The landscape is characterized by:
- Extensive claimsthat cover chemical classes.
- Positioning for combination therapies.
- Focus on compounds with improved selectivity or pharmacokinetics.
Patent Strategies and Trends
Firms seek to secure broad chemical coverage, including derivatives, to prevent infringement. Use of Markush claims is prevalent to cover multiple variants. There is also increasing filing activity around method-of-use patents for specific indications, such as resistance mutation management.
Regional and Global Considerations
While CN patents offer proof of invention and market protection in China, firms seeking wider protection pursue filing in key jurisdictions like the US, EU, and Japan. The Chinese patent landscape reflects an emphasis on domestic innovation and manufacturing, with rising global competitiveness.
Key Takeaways
- CN110678194 covers specific chemical structures of a kinase inhibitor with claims focused on compounds, pharmaceutical compositions, and therapeutic methods.
- The claims are specific but broad within the chemical class, supported by functional data.
- The patent landscape in China for kinase inhibitors is active, with key players targeting broad chemical and indication coverage.
- Patent validity relies on structural novelty and inventive step, with competitors likely to contest if prior art overlaps exist.
- Patent protection extends into the late 2030s, aligning with standard pharmaceutical exclusivity periods in China.
FAQs
Q1: What is the primary therapeutic application of CN110678194?
It targets kinase enzymes, with potential applications in treating cancers.
Q2: How broad are the patent claims?
They cover specific chemical structures, including variants, and extend to pharmaceutical compositions and use methods.
Q3: Can competitors design around this patent?
Yes, if they develop compounds outside the claimed chemical space or use different mechanisms.
Q4: How does this patent compare to global kinase inhibitor patents?
It is similar in scope, focusing on small molecules with specific scaffolds, but tailored for the Chinese market.
Q5: What are the risks of patent invalidation?
Challenges could arise from prior art that discloses similar compounds or from obvious modifications based on existing knowledge.
References:
[1] Chinese Patent CN110678194, 2019.
[2] WIPO. (2021). Patent landscape report on kinase inhibitors.
[3] Chinese Patent Office. (2022). Patent examination guidelines for pharmaceuticals.
